|
Fluconazole Prophylaxis of Thrush in AIDS Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Fluconazole Prophylaxis of Thrush in AIDS conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Fluconazole Prophylaxis of Thrush in AIDS Clinical research trials and Fluconazole Prophylaxis of Thrush in AIDS healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Fluconazole Prophylaxis of Thrush in AIDS. Fluconazole Prophylaxis of Thrush in AIDS Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Fluconazole Prophylaxis of Thrush in AIDS clinical trial. Human subjects often receive the most effective healthcare possible for their Fluconazole Prophylaxis of Thrush in AIDS condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Fluconazole Prophylaxis of Thrush in AIDS  Fluconazole Prophylaxis of Thrush in AIDS
Fluconazole Prophylaxis of Thrush in AIDS
For Condition: Acquired Immunodeficiency Syndrome,Candidiasis,Oral Candidiasis
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: This is a placebo-controlled trial of intermittent fluconazole prophylaxis (200 mg orally three times a week) in the prevention of thrush.
Details: Oropharyngeal candidiasis (OPC) occurs in up to 93% of persons with human immunodeficiency virus (HIV) infection at some time during the course of their illness. OPC usually responds well to initial antifungal therapy, but with increasing immunodeficiency it usually recurs and can become resistant to clinical and microbiologic cure. Therapy usually begins with topical agents, followed by systemic therapy with azole antifungals when those fail. Amphotericin B is also used, but is less well tolerated and usually only effective in parenteral form. Because of its bioavailability and efficacy, fluconazole has become the most commonly used agent in treating OPC. Recurrences have often led to frequent re-treatment or prophylactic therapy with fluconazole. Daily prophylaxis with fluconazole (200 mg) has been shown to decrease the incidence of OPC. With the widespread and prolonged use of fluconazole reports of clinical failures and yeasts with decreased susceptibilities have appeared. This resistance appears to be associated with advanced immunosuppression and azole exposure. The most effective regimen to decrease relapse and morbidity from OPC which minimizes development of resistance has not been established. Could less frequent and/or lower dose prophylaxis with fluconazole decrease the incidence of recurrences while slowing the development of drug resistance? We plan to perform a two phase study of low-dose fluconazole prophylaxis in HIV infected patients with a history of OPC. Patients with advanced immunosuppression (CD4 less than or equal to 150 cell/mm3) who have not received prior fluconazole prophylaxis will be included. Phase 1 of the study will be a placebo-controlled trial of fluconazole at a dose of 200 mg three times weekly. Phase 1 will examine whether this low-dose prophylaxis can delay recurrence of OPC. Phase 2 of the study will be an open-label prophylaxis with fluconazole at first 200mg thrice weekly, then 200mg daily as patients develop recurrent OPC. In this phase the primary question to be answered will be whether subjects starting in the placebo arm of Phase 1 will progress more or less rapidly to clinical fluconazole failure compared to those starting in the fluconazole arm. We will learn more about the natural history of fluconazole resistance, including how gradually the change occurs, how much fluconazole the patient has received at the time resistance develops and whether the resistance occurs in the patient's own isolate or from acquisition of a new isolate. Other evaluations will include compliance, cost, and host and organism-associated factors. If thrice weekly fluconazole prophylaxis can increase the time to development of resistance and decrease episodes of OPC in this group of severely immunocompromised individuals, it would increase the effective use (to include cost-effective use) of fluconazole in the treatment of OPC.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: HIV infection previously documented by ELISA test kit and confirmed by either Western Blot, HIV antigen, HIV culture, or a second antibody test other than ELISA. Age 18 years or older. CD4 count of less than or equal to 150 cells/mm(3). At least one prior episode of health care provider diagnosed oropharyngeal candidiasis in the 6 months preceding enrollment. No allergy or intolerance to azoles. Less than 3 episodes of oropharyngeal candidiasis within the last 3 months. No history of esophageal candidiasis. No presence of systemic fungal infection requiring continuous antifungal therapy. No use of continuous azole treatment (i.e. daily, weekly, every other day, twice weekly fluconazole, itraconazole, ketoconazole or coltrimazole) for the prevention of fungal infections greater than or equal to 1 month within the past 6 months. No severe liver disease (ALT or AST greater than 5 times the upper limit of normal). No history of poorly responsive mucosal infection (i.e., requiring more than 200 mg of fluconazole daily or more than 14 days of therapy). Females may not be pregnant or lactating. Must have a negative pregnancy test within 2 weeks of enrollment. No one unlikely to survive more than 6 months. Must have ability to tolerate oral medications. No presence of active mucosal infection or symptoms of OPC/EC at time of initial assessment. (Note: Can enroll 2 weeks after resolution of the active episode). No patients currently being treated with azole for recent mucosal infection. (Note: These patients can enroll 2 weeks after the completion of azole therapy.) No presence of severe renal insufficiency as indicated by a serum creatinine greater than or equal to 3.0. Women must be taking appropriate birth control measures.
Total Enrollment: 80
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 960108; 96-I-0108
Study Start Date: July 3, 1996
Record last reviewed: November 1, 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001542
Other Candidiasis Studies:
1. Treatment of Depression with Massage in HIV
2. Once-Daily Drug Regimen for HIV-Infected Patients
3. Home Treatment of HIV-Infected Patients with Interleukin-2 with or without a Tumor Necrosis Factor Antagonist
4. Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection
5. Immune Activity Against CVM Retinitis
Related Studies:
Other Candidiasis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Fluconazole Prophylaxis of Thrush in AIDS
|
|
|
|
|
|
|
|
